
Medicine and Health
Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial
P. G. M. D. Gooyer, Y. L. Verschoor, et al.
In a phase 2 trial (NICHE-3), researchers investigated the remarkable effectiveness of neoadjuvant nivolumab combined with relatlimab in patients with locally advanced mismatch repair-deficient colon cancer. With a staggering 97% achieving a pathologic response, including 68% demonstrating complete responses, these findings highlight the therapy's promise for further studies. This groundbreaking research was conducted by Peter G. M. de Gooyer and colleagues from the Netherlands Cancer Institute.
~3 min • Beginner • English
Related Publications
Explore these studies to deepen your understanding of the subject.